154 related articles for article (PubMed ID: 32490370)
1. Cost-effectiveness analysis of pre-ART HIV drug resistance testing in Kenyan women.
Duarte HA; Babigumira JB; Enns EA; Stauffer DC; Shafer RW; Beck IA; Garrison LP; Chung MH; Frenkel LM; Bendavid E
EClinicalMedicine; 2020 May; 22():100355. PubMed ID: 32490370
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial.
Chung MH; McGrath CJ; Beck IA; Levine M; Milne RS; So I; Andersen N; Dross S; Coombs RW; Chohan B; Yatich N; Kiptinness C; Sakr SR; Kiarie JN; Frenkel LM
Lancet HIV; 2020 Feb; 7(2):e104-e112. PubMed ID: 31818716
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru.
Soria J; Mugruza R; Levine M; León SR; Arévalo J; Ticona E; Beck IA; Frenkel LM
AIDS Res Hum Retroviruses; 2019 Feb; 35(2):150-154. PubMed ID: 30560685
[TBL] [Abstract][Full Text] [Related]
4. Implementation of a point mutation assay for HIV drug resistance testing in Kenya.
Duarte HA; Beck IA; Levine M; Kiptinness C; Kingoo JM; Chohan B; Sakr SR; Chung MH; Frenkel LM
AIDS; 2018 Oct; 32(16):2301-2308. PubMed ID: 30005020
[TBL] [Abstract][Full Text] [Related]
5. Pre-treatment HIV-drug resistance associated with virologic outcome of first-line NNRTI-antiretroviral therapy: A cohort study in Kenya.
Beck IA; Levine M; McGrath CJ; Bii S; Milne RS; Kingoo JM; So I; Andersen N; Dross S; Coombs RW; Kiarie J; Chohan B; Sakr SR; Chung MH; Frenkel LM
EClinicalMedicine; 2020 Jan; 18():100239. PubMed ID: 31956856
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study.
Phillips AN; Cambiano V; Nakagawa F; Revill P; Jordan MR; Hallett TB; Doherty M; De Luca A; Lundgren JD; Mhangara M; Apollo T; Mellors J; Nichols B; Parikh U; Pillay D; Rinke de Wit T; Sigaloff K; Havlir D; Kuritzkes DR; Pozniak A; van de Vijver D; Vitoria M; Wainberg MA; Raizes E; Bertagnolio S;
Lancet HIV; 2018 Mar; 5(3):e146-e154. PubMed ID: 29174084
[TBL] [Abstract][Full Text] [Related]
7. Minority and majority pretreatment HIV-1 drug resistance associated with failure of first-line nonnucleoside reverse-transcriptase inhibitor antiretroviral therapy in Kenyan women.
Milne RS; Silverman RA; Beck IA; Mckernan-Mullin J; Deng W; Sibley TR; Dross S; Kiarie JN; Sakr SR; Coombs RW; Chung MH; Frenkel LM
AIDS; 2019 May; 33(6):941-951. PubMed ID: 30946148
[TBL] [Abstract][Full Text] [Related]
8. Addressing Pediatric HIV Pretreatment Drug Resistance and Virologic Failure in Sub-Saharan Africa: A Cost-Effectiveness Analysis of Diagnostic-Based Strategies in Children ≥3 Years Old.
Siriruchatanon M; Liu S; Carlucci JG; Enns EA; Duarte HA
Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33801154
[TBL] [Abstract][Full Text] [Related]
9. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
[TBL] [Abstract][Full Text] [Related]
10. Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study.
Hauser A; Kusejko K; Johnson LF; Günthard HF; Riou J; Wandeler G; Egger M; Kouyos RD
PLoS Med; 2020 Dec; 17(12):e1003397. PubMed ID: 33315863
[TBL] [Abstract][Full Text] [Related]
11. Near point-of-care, point-mutation test to detect drug resistance in HIV-1: a validation study in a Mexican cohort.
Panpradist N; Beck IA; Ruth PS; Ávila-Ríos S; García-Morales C; Soto-Nava M; Tapia-Trejo D; Matías-Florentino M; Paz-Juarez HE; Del Arenal-Sanchez S; Reyes-Terán G; Lutz BR; Frenkel LM
AIDS; 2020 Jul; 34(9):1331-1338. PubMed ID: 32205723
[TBL] [Abstract][Full Text] [Related]
12. High levels of pre-treatment HIV drug resistance and treatment failure in Nigerian children.
Boerma RS; Boender TS; Sigaloff KC; Rinke de Wit TF; van Hensbroek MB; Ndembi N; Adeyemo T; Temiye EO; Osibogun A; Ondoa P; Calis JC; Akanmu AS
J Int AIDS Soc; 2016; 19(1):21140. PubMed ID: 27836020
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment HIV Drug Resistance Among Adults Initiating or Re-Initiating First-Line Antiretroviral Therapy in Zimbabwe: Fast-Tracking the Transition to Dolutegravir-Based First-Line Regimens?
Kouamou V; Mavetera J; Manasa J; Ndhlovu CE; Katzenstein D; McGregor AM
AIDS Res Hum Retroviruses; 2021 Oct; 37(10):776-783. PubMed ID: 33430681
[TBL] [Abstract][Full Text] [Related]
14. Trends in HIV-1 pretreatment drug resistance and HIV-1 variant dynamics among antiretroviral therapy-naive Ethiopians from 2003 to 2018: a pooled sequence analysis.
Kiros M; Biset S; Gebremariam B; Yalew GT; Abegaz WE; Geteneh A
Virol J; 2023 Oct; 20(1):243. PubMed ID: 37880705
[TBL] [Abstract][Full Text] [Related]
15. Oligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya.
Chung MH; Beck IA; Dross S; Tapia K; Kiarie JN; Richardson BA; Overbaugh J; Sakr SR; John-Stewart GC; Frenkel LM
J Acquir Immune Defic Syndr; 2014 Nov; 67(3):246-53. PubMed ID: 25140907
[TBL] [Abstract][Full Text] [Related]
16. Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005-2013.
McCluskey SM; Lee GQ; Kamelian K; Kembabazi A; Musinguzi N; Bwana MB; Muzoora C; Haberer JE; Hunt PW; Martin JN; Boum Y; Bangsberg DR; Harrigan PR; Siedner MJ
AIDS Patient Care STDS; 2018 Jul; 32(7):257-264. PubMed ID: 29985647
[TBL] [Abstract][Full Text] [Related]
17. HIV pretreatment drug resistance among cisgender MSM and transgender women from Lima, Peru.
Trebelcock WL; Lama JR; Duerr A; Sanchez H; Cabello R; Gilada T; Segura P; Reisner SL; Mayer KH; Mullins J; Bender Ignacio RA
J Int AIDS Soc; 2019 Nov; 22(11):e25411. PubMed ID: 31773888
[TBL] [Abstract][Full Text] [Related]
18. HIV Drug Resistance in Antiretroviral Treatment-Naïve Individuals in the Largest Public Hospital in Nicaragua, 2011-2015.
Avila-Ríos S; García-Morales C; Matías-Florentino M; Tapia-Trejo D; Hernández-Álvarez BF; Moreira-López SE; Quant-Durán CJ; Porras-Cortés G; Reyes-Terán G
PLoS One; 2016; 11(10):e0164156. PubMed ID: 27736898
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis.
Phillips AN; Cambiano V; Miners A; Revill P; Pillay D; Lundgren JD; Bennett D; Raizes E; Nakagawa F; De Luca A; Vitoria M; Barcarolo J; Perriens J; Jordan MR; Bertagnolio S
Lancet HIV; 2014 Nov; 1(2):e85-93. PubMed ID: 26423990
[TBL] [Abstract][Full Text] [Related]
20. Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial.
Derache A; Iwuji CC; Baisley K; Danaviah S; Marcelin AG; Calvez V; de Oliveira T; Dabis F; Porter K; Pillay D
Clin Infect Dis; 2019 Jul; 69(2):207-214. PubMed ID: 30321314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
